Sclerostin: A key protein for cardiovascular health in patients with type 2 diabetes
Type 2 diabetes (T2D) is a growing concern as the metabolic disorder is associated with an increased risk of cardiovascular disease (CVD) affecting approximately 35% of T2D patients. The major CVDs associated with T2D include ischemic heart disease, coronary artery disease, and peripheral artery disease.
A study in Cardiovascular Diabetology carried out by the MP20-Biomarkers of Metabolic and Bone Diseases research group at the Biohealth Research Institute in Granada (ibs.GRANADA), led by UGR Professor Manuel Muñoz Torres, has provided significant insights into the role of sclerostin in protecting against atherosclerosis in patients with type 2 diabetes.
Sclerostin, commonly associated with the regulation of bone formation, has emerged as a protective factor in vascular health, especially in individuals with type 2 diabetes. Atherosclerosis, a common complication of this disease, involves the deposition of substances such as cholesterol and fats in the arteries, resulting in the formation of plaques that can reduce blood flow and increase the risk of serious cardiovascular diseases.
The study, led by Professor Manuel Muñoz Torres, together with Dr Beatriz García Fontana and Dr Cristina García Fontana, included 121 controls and 139 patients with type 2 diabetes (48 with cardiovascular disease and 91 without). The results showed significantly higher levels of sclerostin in patients with type 2 diabetes and cardiovascular disease, suggesting a possible link between this protein and atherosclerosis. Sclerostin was also shown to play a beneficial role in reducing arterial calcification, which is associated with the development of atherosclerosis.
The group of scientists from ibs.GRANADA, the “San Cecilio” University Hospital in Granada, the Centre for Networked Biomedical Research on Frailty and Healthy Ageing (CIBERFES) of the “Carlos III” Health Institute, as well as the UGR, carried out in vitro experiments on vascular smooth muscle cells, replicating pathophysiological conditions of patients with type 2 diabetes. They found that sclerostin overexpression reduced calcium deposits, decreased cell proliferation and inflammation, and promoted cell survival.
The results, part of researcher Sheila González Salvatierra’s doctoral thesis, raise concerns about the use of anti-sclerostin antibody treatments in patients with type 2 diabetes, as blocking sclerostin activity may increase cardiovascular risk. This discovery highlights the importance of following regulatory guidelines when prescribing these medications, which are contraindicated in people with high cardiovascular risk.
Researchers concluded that "Sclerostin could play a protective role in the development of atherosclerosis in T2D patients by reducing calcium deposits, decreasing proliferation and inflammation, and promoting cell survival in VSMCs under calcifying conditions. Therefore, considering the bone-vascular axis, treatment with anti-sclerostin for bone disease should be used with caution."
The authors of the study noted the clinical relevance of these findings, which have the potential to significantly impact therapeutic strategies for patients with type 2 diabetes and cardiovascular disease.
Reference:
González-Salvatierra, S., García-Fontana, C., Lacal, J. et al. Cardioprotective function of sclerostin by reducing calcium deposition, proliferation, and apoptosis in human vascular smooth muscle cells. Cardiovasc Diabetol 22, 301 (2023). https://doi.org/10.1186/s12933-023-02043-8.
